



CEORL-HNS 2026

Medical Symposium

Agenda

Sunday 26 April 2026 | 13:00–14:00 CET

Swedish Exhibition & Congress Centre and Gothia Towers,
Gothenburg, Sweden

This symposium is organised and funded by AstraZeneca and is for healthcare professionals only. The content presented at this meeting has been reviewed and approved by AstraZeneca prior to the meeting. EpiCentral is sponsored by AstraZeneca. © 2026 AstraZeneca. All Rights Reserved.

Veeva ID: SE-21422; date of preparation: March 2026.



EpiCentral
UNDERSTANDING THE CENTRAL ROLE OF THE
EPITHELIUM IN SEVERE ASTHMA AND BEYOND



Prof Claire Hopkins
King's College London /
Guy's & St Thomas' Hospital



Prof Eugenio De Corso
Catholic University of the
Sacred Heart



Chair and Speaker

Speaker



Symposium

Overarching goal: To provide an overview and enhance understanding of biologic treatment options for CRSwNP

Objectives

- Explore the core domains of **'epithelial health'** and how **epithelial dysfunction** can contribute to CRSwNP disease pathogenesis
- Raise awareness of the **unmet needs** for patients with CRSwNP that can lead to a **cycle of recurrence** and **epithelial-driven inflammation**
- Explore the importance of addressing **epithelial-driven inflammation** and **targeting epithelial cytokines** to improve patient outcomes
- Share the **latest data** from pivotal trials and **real-world evidence** in patients with CRSwNP with and without comorbid asthma treated with available biologics
- Discuss approaches to **managing disease trajectory** for patients with CRSwNP, CRSwNP with comorbid asthma, and asthma with comorbid CRSwNP

Agenda

Time	Topic	Presenter
13:00	Welcome and introduction	Claire Hopkins
13:05	Importance of addressing epithelial-driven inflammation in CRSwNP	Eugenio De Corso
13:20	Impact of biologics on treatment of CRSwNP	Claire Hopkins
13:40	Patient case discussion/polling	All faculty, led by Eugenio De Corso
13:55	Summary and close	Claire Hopkins

CRSwNP, chronic rhinosinusitis with nasal polyps.

This symposium is organised and funded by AstraZeneca and is for healthcare professionals only. The content presented at this meeting has been reviewed and approved by AstraZeneca prior to the meeting.

EpiCentral is sponsored by AstraZeneca. © 2026 AstraZeneca. All Rights Reserved.

Veeva ID: SE-21422; date of preparation: March 2026.

Detailed agenda

Time	Topic	Presenter
13:00 (5 mins)	Welcome and introduction	Claire Hopkins
13:05 (15 mins)	Importance of addressing epithelial-driven inflammation in CRSwNP <ul style="list-style-type: none"> Outline the unmet needs for patients with CRSwNP, including the cycle of recurrence and damage Explore the evolution in the understanding of the inflammatory processes underlying CRSwNP, highlighting how environmental triggers lead to epithelial activation, which drives disease pathogenesis Outline the core domains describing 'epithelial health' and the role of epithelial dysfunction in CRSwNP Introduce epithelial cytokines as targets for improving patient outcomes 	Eugenio De Corso
13:20 (20 mins)	Impact of biologics on treatment of CRSwNP <ul style="list-style-type: none"> Introduce the mechanism of action of biologics currently available for treatment of CRSwNP <ul style="list-style-type: none"> Present an overview of data from first-generation biologics (dupilumab, mepolizumab and omalizumab) in CRSwNP Present data from second-generation biologics (tezepelumab and depemokimab) from pivotal clinical trials for patients with CRSwNP with and without comorbid asthma 	Claire Hopkins
13:40 (15 mins)	Patient case discussion/polling <ul style="list-style-type: none"> Faculty to discuss approaches to managing patients with CRSwNP with and without comorbid asthma through real-world case studies <ul style="list-style-type: none"> Outline patient demographics and diagnostic journey to date, and discuss management options for this patient Potential for use of audience polling at diverging points in the management strategy, ensuring questions and discussion is focused on therapeutic classes over named therapies 	All faculty, led by Eugenio De Corso
13:55 (5 mins)	Summary and close	Claire Hopkins

CRSwNP, chronic rhinosinusitis with nasal polyps.

This symposium is organised and funded by AstraZeneca and is for healthcare professionals only. The content presented at this meeting has been reviewed and approved by AstraZeneca prior to the meeting.

EpiCentral is sponsored by AstraZeneca. © 2026 AstraZeneca. All Rights Reserved.

Veeva ID: SE-21422; date of preparation: March 2026.